Crinetics Pharmaceuticals CRNX

$ 53.4 1.25%

Quarterly report 2024-Q3
added 11-12-2024

Crinetics Pharmaceuticals Balance Sheet 2011-2024 | CRNX

Annual Balance Sheet Crinetics Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-3.17 M	-29.6 M	-198 M	-89.1 M	-35.5 M	-45 M	-14.2 M	-11.9 M	-	-	-	-	-
Long Term Debt	47.6 M	2.02 M	3.07 M	4.01 M	-	-	-	163 K	-	-	-	-	-
Long Term Debt Current	4.17 M	1.05 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	4.9 M	3.26 M	29.7 M	17.9 M	-	-	-	-	-
Total Current Liabilities	43.9 M	27.7 M	16 M	10.5 M	8.34 M	7.92 M	-	-	-	-	-	-	-
Total Liabilities	96.2 M	35.8 M	19.1 M	14.5 M	13.2 M	11.2 M	30.6 M	18.8 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-654 M	-439 M	-275 M	-	-93.8 M	-43.4 M	-16.3 M	-7.11 M	-	-	-	-	-
Total Assets	635 M	352 M	351 M	183 M	130 M	171 M	15.6 M	12.6 M	-	-	-	-	-
Cash and Cash Equivalents	54.9 M	32.7 M	201 M	93.1 M	40.3 M	45 M	14.2 M	12.2 M	-	-	-	-	-
Book Value	539 M	316 M	332 M	169 M	117 M	160 M	-15 M	-6.2 M	-	-	-	-	-
Total Shareholders Equity	539 M	316 M	332 M	169 M	117 M	160 M	-15 M	-6.2 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Crinetics Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	45.1 M	45.9 M	46.7 M	47.6 M	48.2 M	1.46 M	1.74 M	2.02 M	2.3 M	2.56 M	2.82 M	3.07 M	3.32 M	3.56 M	3.79 M	4.01 M	4.01 M	4.01 M	4.01 M	4.85 M	4.85 M	4.85 M	4.85 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	104 M	105 M	103 M	96.2 M	93.8 M	39.1 M	33.7 M	35.8 M	33.5 M	35.6 M	30.2 M	19.1 M	15.8 M	15.5 M	14.1 M	14.5 M	14.5 M	14.5 M	14.5 M	13.2 M	13.2 M	13.2 M	13.2 M	11.2 M	11.2 M	11.2 M	11.2 M	920 K	920 K	920 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	1.68 M	2.56 M	-	2.06 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-872 M	-795 M	-721 M	-654 M	-594 M	-536 M	-485 M	-439 M	-394 M	-352 M	-310 M	-275 M	-244 M	-217 M	-191 M	-168 M	-168 M	-168 M	-168 M	-93.8 M	-93.8 M	-93.8 M	-93.8 M	-43.4 M	-43.4 M	-43.4 M	-43.4 M	-16.3 M	-16.3 M	-16.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	937 M	936 M	978 M	635 M	642 M	293 M	314 M	352 M	385 M	422 M	333 M	351 M	209 M	217 M	164 M	183 M	183 M	183 M	183 M	130 M	130 M	130 M	130 M	171 M	171 M	171 M	171 M	15.6 M	15.6 M	15.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	317 M	302 M	396 M	54.9 M	143 M	39.6 M	41.2 M	32.7 M	30.9 M	62.3 M	146 M	201 M	162 M	179 M	106 M	93.1 M	93.1 M	93.1 M	93.1 M	40.3 M	40.3 M	40.3 M	40.3 M	45 M	45 M	45 M	45 M	14.2 M	14.2 M	14.2 M	-	12.2 M	-	-	-	17.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	833 M	831 M	875 M	539 M	548 M	254 M	280 M	316 M	351 M	386 M	303 M	332 M	194 M	201 M	149 M	169 M	169 M	169 M	169 M	117 M	117 M	117 M	117 M	160 M	160 M	160 M	160 M	14.7 M	14.7 M	14.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	833 M	831 M	875 M	539 M	548 M	254 M	280 M	316 M	351 M	386 M	303 M	332 M	194 M	201 M	149 M	169 M	169 M	169 M	169 M	117 M	117 M	117 M	117 M	160 M	160 M	160 M	160 M	-15 M	-15 M	-15 M	-	-6.2 M	-	-	-	-463 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency